Are you Dr. Munn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1120 15th St
Augusta, GA 30912Phone+1 706-721-3626Fax+1 706-721-2643
Summary
- Dr. David Munn, MD is a pediatric hematologist/oncologist in Augusta, Georgia. He is currently licensed to practice medicine in Georgia. He is a Professor at Medical College of Georgia at Georgia Health Sciences University.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1987 - 1990
- Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 1984 - 1987
- Medical College of Georgia at Augusta UniversityClass of 1984
Certifications & Licensure
- GA State Medical License 1990 - 2015
Publications & Presentations
PubMed
- 10 citationsIndoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial.Theodore S Johnson, Tobey J MacDonald, Rafal Pacholczyk, Dolly Aguilera, Ahmad Al-Basheer
Neuro-Oncology. 2024-02-02 - 5 citationsEnniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer.Nada H Eisa, Vincent M Crowley, Asif Elahi, Vamsi Krishna Kommalapati, Michael A Serwetnyk
Iscience. 2023-12-15 - 47 citationsTumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment.John D Klement, Priscilla S Redd, Chunwan Lu, Alyssa D Merting, Dakota B Poschel
Cancer Cell. 2023-03-13
Press Mentions
- Novel Immunotherapy Beneficial to Children with Relapsed Brain Tumours: ResearchApril 25th, 2023
- Novel Treatment Regimen Appears Well Tolerated, Beneficial to Children with Relapsed Brain TumorsApril 25th, 2023
- Loss of Indoleamine-2,3-Dioxygenase-1 (IDO1) in Knockout Mice Does Not Affect the Development of Skin Lesions in the Imiquimod-Induced Mouse Model of PsoriasisFebruary 28th, 2022
- Join now to see all
Grant Support
- Ido-Mediated Immune Regulation In Established TumorsNational Cancer Institute2010–2012
- Role Of IDO MalignancyNational Cancer Institute2010–2011
- Ido-Expressing Immunoregulatory Dendritic CellsNational Cancer Institute2010–2011
- Role Of IDO MalignancyNational Cancer Institute2007–2009
- Ido-Expressing Plasmacytoid Dendritic Cells And TumorsNational Cancer Institute2005–2009
- Ido-Expressing Immunoregulatory Dendritic CellsNational Cancer Institute2003–2009
- Role Of IDO In MalignancyNational Cancer Institute2003–2006
- Macrophage Mediated Immunoregulation VIA TryptophanNational Heart, Lung, And Blood Institute1999–2002
- Inhibition Of T Cells By Tryptophan DegradationNational Institute Of Allergy And Infectious Diseases1998–1999
- Regulation Of Macrophage ApoptosisNational Heart, Lung, And Blood Institute1995–1997